Natural history of patients with venous thromboembolism and hereditary hemorrhagic telangiectasia. Findings from the RIETE registry
Riera Mestre, Antoni (Hospital Universitari de Bellvitge)
Mora-Luján, José María (Hospital Universitari de Bellvitge)
Trujillo-Santos, Javier (Hospital General Universitario Santa Lucía (Cartagena, Múrcia))
Del Toro, Jorge (Hospital General Universitario Gregorio Marañón)
Nieto, José Antonio (Hospital Virgen de La Luz (Cuenca))
Pedrajas, José María (Hospital Clínico San Carlos (Madrid))
López-Reyes, Raquel (Hospital Universitari i Politècnic La Fe (València))
Soler, Silvia (Fundació Hospital d'Olot i Comarcal de la Garrotxa)
Ballaz, Aitor (Hospital de Galdakao (Usansolo, Biscaia))
Cerdà, Pau (Hospital Universitari de Bellvitge)
Monreal, Manel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Universitat Autònoma de Barcelona

Data:	2019
Resum:	Background: Limited data exist about the clinical presentation, ideal therapy and outcomes of patients with hereditary hemorrhagic telangiectasia (HHT) who develop venous thromboembolism (VTE). Methods: We used the data in the RIETE Registry to assess the clinical characteristics, therapeutic approaches and clinical outcomes during the course of anticoagulant therapy in patients with HHT according to initial presentation as pulmonary embolism (PE) or deep venous thrombosis (DVT). Results: Of 51,375 patients with acute VTE enrolled in RIETE from February 2009 to January 2019, 23 (0. 04%) had HHT: 14 (61%) initially presented with PE and 9 (39%) with DVT alone. Almost half (47. 8%) of the patients with VTE had a risk factor for VTE. Most PE and DVT patients received low-molecular-weight heparin for initial (71 and 100%, respectively) and long-term therapy (54 and 67%, respectively). During anticoagulation for VTE, the rate of bleeding events (major 2, non-major 6) far outweighed the rate of VTE recurrences (recurrent DVT 1): 50. 1 bleeds per 100 patient-years (95%CI: 21. 6-98. 7) vs. 6. 26 recurrences (95%CI: 0. 31-30. 9; p = 0. 020). One major and three non-major bleeding were epistaxis. No patient died of bleeding. One patient died shortly after being diagnosed with acute PE. Conclusions: During anticoagulation for VTE in HHT patients, there were more bleeding events than VTE recurrences. Most bleeding episodes were non-major epistaxis.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Deep venous thrombosis ; Hemorrhagic hereditary telangiectasia ; Pulmonary embolism ; Rare diseases ; Venous thromboembolism
Publicat a:	Orphanet Journal of Rare Diseases, Vol. 14 Núm. 1 (september 2019) , p. 196, ISSN 1750-1172

DOI: 10.1186/s13023-019-1172-8
PMID: 31399146

8 p, 589.1 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles de recerca
Articles > Articles publicats